Aleniglipron

GSBR-1290, oral GLP-1Not a peptide · small-molecule pillMetabolic/Weight

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight loss

MechanismDaily oral small-molecule GLP-1 receptor agonist.

EffectsAbout 15.3% weight loss reported in trial. Across all studies to date there were no cases of drug-induced liver injury, no persistent liver enzyme elevation and no QTc prolongation.

DosingNo human dose established.

Bottom lineA clean liver-safety record so far, which matters in a class where that has ended at least one programme.

Not a dose · what the literature contains instead

The Phase 3 design starts titration at 2.5 mg with the intent to evaluate doses up to 240 mg; the Phase 2b open-label extension titrates monthly to a 120 mg target.

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

Investigational and not approved. GI effects consistent with the class. Over 200 patients treated without serious adverse events, but Phase 3 has not read out.

Expected GLP-1 class behaviour; not formally studied.

CV 2 of 5 — No QTc prolongation observed across studies. No cardiovascular outcomes data.